A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Clinical and Safety of DiaPep277 in Newly Diagnosed Type 1 Diabetes Subjects
| City: |
|
Las Vegas |
| State: |
|
Nevada |
| Zip Code: |
|
89148 |
| Conditions: |
|
Type 1 Diabetes Mellitus |
| Purpose: |
|
This study will look at the treatment effect of DiaPep277 on preservation of beta-cell
function, as defined by meal-stimulated secretion of insulin. DiaPep277 is a peptide that
changes the way the immune system behaves, stopping its attack on the beta-cells.
Adults (>20 years) with newly diagnosed (<6 months) type 1 diabetes will be treated with 10
injections of DiaPep277 or Placebo over a 2-year treatment and follow-up period.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- clinical diagnosis of type 1 diabetes within last 6 months
- Age 20-45 years
- fasting basal C-peptide equal or greater than 0.22nmol/L, lower than 0.8nmol/L
- BMI between 17 and 30 at screening
Exclusion Criteria:
- Significant disease or condition other than type 1 diabetes
- Diabetes-related complications
- Ongoing treatment with immunosuppressive or immunomodulating agents including
chronic corticosteroids
|
| NCT ID: |
|
NCT01103284 |
| Primary Contact: |
|
Principal Investigator
Itamar Raz, MD
Hadassah Medical Center, Jerusalem
Merana Tamir, Ph.D.
Phone: +972 8 9387730
Email: merana@andromedabio.com
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Las Vegas, Nevada 89148
United States
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 24, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|